EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces that the reduction of the Company's share capital necessary in order for the Company to proceed with its share buyback plan of up to 15% of the Company's current issued share capital has now been approved by the court.

Details of the reduction of capital were set out in the circular to shareholders dated 26 June 2017 and the proposal was approved by shareholders at the General Meeting held on 27 July 2017.

The Company is currently in a close period ahead of the publication of its interim results on 11 September 2017 and further announcements will be made in connection with the commencement of the share buyback at the appropriate time.

EKF Diagnostics Holdings plc

Christopher Mills, Non-Executive Chairman

Julian Baines, CEO

Richard Evans, FD & COO

www.ekfdiagnostics.com
Tel: 029 2071 0570
N+1 Singer (Nomad & Broker)
Alex Price / Shaun Dobson / Ali Laughton-Scott
Tel: 020 7496 3000

Walbrook PR Limited
Paul McManus
Lianne Cawthorne

Tel: 020 7933 8780 or ekf@walbrookpr.com
Mob: 07980 541 893 / 07584 391 303

EKF Diagnostics Holdings plc published this content on 06 September 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 06 September 2017 13:17:06 UTC.

Original documenthttps://www.ekfdiagnostics.com/reduction-of-capital.html

Public permalinkhttp://www.publicnow.com/view/5E7537E72A7D183B4596B79BE300CBB519999C65